Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026, held today. The approved motions included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members. However, the motions for the extraordinary part of the meeting were not put to a vote because the required quorum was not reached.
The company, a biopharmaceutical firm focused on novel therapies for central and peripheral nervous system diseases, emphasized the importance of the new appointments. Chris Martin, Chairman of the Board of Directors, expressed gratitude to shareholders for their trust and welcomed the new members. He also thanked Patrick Langlois and Luca Benatti, who stepped down after long-standing service, for their support.
Newron's lead compound, evenamide, is a first-in-class glutamate modulator with potential as an add-on therapy for treatment-resistant schizophrenia (TRS) and poorly responding patients. It is currently in the global pivotal ENIGMA-TRS Phase III development program, with clinical results showing significant improvements in efficacy measures and a favorable safety profile. The company has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, and with Myung In Pharm for South Korea.
Newron's first marketed product, Xadago® (safinamide), is approved for Parkinson's disease in multiple regions, including the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by partners Zambon, Supernus Pharmaceuticals (U.S.), and Meiji Seika (Japan and key Asian territories).
For more information, visit www.newron.com or view the original release on www.newmediawire.com.
